NCT00743860已完成1 期
A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and Its Metabolites in Healthy Volunteers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Clinical safety data (spontaneous AE reporting, vital signs, nursing/physician observation, and clinical laboratory tests) will be the primary safety endpoint.
研究概览
简要总结
This study is designed to assess the pharmacokinetics of darapladib and its metabolites following single and 28 days of repeat dosing of darapladib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG.
- •Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- •A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
- •Child-bearing potential and agrees to use one of the contraception methods per protocol for an appropriate period of time prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit.
- •Body weight >50 kg and BMI within the range 19 - 30 kg/m2 (inclusive).
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
排除标准
- •A positive pre-study drug/alcohol screen.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication
- •Consumption of grapefruit or grapefruit juice within 7 days prior to first dose of study medication.
- •History of drug abuse.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions or severe allergic responses.
- •History of cholecystectomy or biliary tract disease, or a history of liver disease with elevated liver function tests of known or unknown etiology.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia (if heparin is to be used for flushing a cannula).
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Use of oral, injected and implanted hormonal methods of contraception for female subjects.
- •Pregnant females as determined by positive serum hCG test at screening or prior to dosing.
- •Lactating females.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Subject is mentally or legally incapacitated.
研究组 & 干预措施
Repeat Dose
Experimental
28 day repeat dose
干预措施: darapladib (Drug)
Single dose
Experimental
single oral dose
干预措施: darapladib (Drug)
结局指标
主要结局
Clinical safety data (spontaneous AE reporting, vital signs, nursing/physician observation, and clinical laboratory tests) will be the primary safety endpoint.
时间窗: throughout study
The primary PK endpoints will include AUC and Cmax of darapladib and its metabolites (M10, M3 and M4) following single and repeat oral doses. Metabolite to parent AUC and Cmax ratio for each metabolite will be calculated as data permit.
时间窗: following single and 28 day repeat dose
次要结局
- Plasma Lp-PLA2 activity, expressed in terms of percent inhibition relative to baseline, as data permit.(following single and repeat dose)
- Secondary PK endpoints will include Tmax and T½ of darapladib and its metabolites (M10, M3 and M4) as data permit.(following single and 28 day repeat dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate Darapladib in Moderately Hepatically Impaired SubjectsAtherosclerosisNCT01154114GlaxoSmithKline24
已完成
1 期
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic PainPainAnalgesics, OpioidNCT00410878Alza Corporation, DE, USA22
进行中（未招募）
1 期
Estudio de resultados clínicos de darapladib en comparación con placebo en pacientes con síndrome coronario agudo, para comparar la incidencia de acontecimientos cardiovasculares adversos importantes (ACAI).(Título abreviado: Ensayo sobre la estabilización de placas con darapladib-trombólisis en el infarto de miocardio (Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52,[SOLID-TIMI 52]).A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).(Short title: The Stabilization Of pLaques usIng Darapladib- Thrombolysis In Myocardial Infarction 52 [SOLID-TIMI 52] Trial) - SOLID-TIMI 52Después de un síndrome coronario agudo (SCA) reciente. after recent Acute Coronary Syndrome (ACS).MedDRA version: 12.0Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2009-012581-32-ESGlaxoSmithKline Research & Development, Ltd13,026
已完成
2 期
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid MalignanciesNon-Myeloid MalignanciesCancerAnemiaNCT00239239Amgen44
尚未招募
1 期
Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315Healthy VolunteersNCT06592495Daewoong Pharmaceutical Co. LTD.52